Arena Pharmaceuticals to Report Fourth Quarter and Full Year 2007 Financial Results and to Host Conference Call and Webcast on Wednesday, February 27, 2008
SAN DIEGO, Feb. 20 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc.
(Nasdaq: ARNA) today announced it will report fourth quarter and full year
2007 financial results after the NASDAQ Global Market closes on Wednesday,
February 27, 2008. That same afternoon, Jack Lief, Arena's President and Chief
Executive Officer, and Robert E. Hoffman, Arena's Vice President, Finance and
Chief Financial Officer, will host a conference call at 5:00 p.m. Eastern Time
(2:00 p.m. Pacific Time) to discuss the financial results for the fourth
quarter and full year 2007 and to provide 2008 financial guidance and a
The conference call may be accessed by dialing 866.356.4281 for domestic
callers and 617.597.5395 for international callers. Please specify to the
operator that you would like to join the "Arena Fourth Quarter and Full Year
Earnings Call." The participant code for the call is 19957700. The conference
call will be webcast live under the investor relations section of Arena's
website at http://www.arenapharm.com, and will be archived there for 30 days
following the call. Please connect to Arena's website several minutes prior to
the start of the broadcast to ensure adequate time for any software download
that may be necessary.
About Arena Pharmaceuticals
Arena is a clinical-stage biopharmaceutical company focused on
discovering, developing and commercializing oral drugs in four major
therapeutic areas: cardiovascular, central nervous system, inflammatory and
metabolic diseases. Arena's most advanced drug candidate, lorcaserin, is being
investigated in a Phase 3 clinical trial program for the treatment of obesity.
Arena's broad pipeline of novel compounds targeting G protein-coupled
receptors, an important class of validated drug targets, includes compounds
being evaluated independently and with its partners, Merck & Co., Inc. and
Ortho-McNeil Pharmaceutical, Inc.
Arena Pharmaceuticals® and Arena® are registered service marks of the
company. "APD" is an abbreviation for Arena Pharmaceuticals Development.
Certain statements in this press release are forward-looking statements
that involve a number of risks and uncertainties. Such forward-looking
statements include statements about Arena's strategy, internal and partnered
programs, and ability to develop compounds and commercialize drugs. For such
statements, Arena claims the protection of the Private Securities Litigation
Reform Act of 1995. Actual events or results may differ materially from
Arena's expectations. Factors that could cause actual results to differ
materially from the forward-looking statements include, but are not limited
to, planned clinical trials and studies may not proceed at the time or in the
manner Arena expects or at all, the results of preclinical studies or clinical
trials may not be predictive of future results, Arena's ability to partner
lorcaserin, APD125, APD791 or other of its compounds or programs, the timing,
success and cost of Arena's research, out-licensing endeavors and clinical
trials, Arena's ability to obtain additional financing, Arena's ability to
obtain and defend its patents, and the timing and receipt of payments and
fees, if any, from Arena's collaborators. Additional factors that could cause
actual results to differ materially from those stated or implied by Arena's
forward-looking statements are disclosed in Arena's filings with the
Securities and Exchange Commission. These forward-looking statements represent
Arena's judgment as of the time of this release. Arena disclaims any intent or
obligation to update these forward-looking statements, other than as may be
required under applicable law.
SOURCE Arena Pharmaceuticals, Inc.
CONTACT: Jack Lief, President and CEO, or David Walsey, Director,
Corporate Communications, both of Arena Pharmaceuticals, Inc.,
+1-858-453-7200, ext. 1682; or Mary Claire Duch of WeissComm Partners, Media
Relations, +1-212-301-7228, for Arena Pharmaceuticals, Inc.